^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The following targeted agents are recommended (category 2A) for patients with emerging genetic variants...cabozantinib or vandetanib (for RET fusions)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vandetanib in Advanced NSCLC With RET Rearrangement

    Excerpt:
    ...- Presence of a RET fusion in an archival or newly acquired NSCLC tumor specimen (RET fusion should be performed in central laboratory by FISH)...
    Trial ID:
    NCT01823068